Cytokinetics, Incorporated — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-1.6% -$2M
$-132M
Free Cash Flow↓-337.5% -$4M
$-6M
Investing Cash Flow
$53M
Financing Cash Flow↑+4543.7% +$108M
$111M
Capex↑+337.5% +$4M
$6M
Stock Buybacks
—
Stock-Based Comp↑+16.2% +$4M
$31M
Debt Repaid↑+1.9% +$51K
$3M
D&A↑+20.1% +$478K
$3M
SBC Allocated Expense↑+16.2% +$4M
$31M
SBC Unrecognized Cost
$11M